Trial · NCT07907640
Real-world Effectiveness and Safety of Savagen (Sacubitril/Valsartan) in Malaysian HFrEF Patients
NCT07907640, Not yet recruiting, Sunway University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Real-world Effectiveness and Safety of Savagen (Sacubitril/Valsartan) in Malaysian HFrEF Patients. Trials, record NCT07907640. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907640
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Real-world Effectiveness and Safety of Savagen (Sacubitril/Valsartan) in Malaysian HFrEF Patients
- NCT number
- NCT07907640
- Status
- Not yet recruiting
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Sunway University
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure
- Interventions
- Savagen (sacubitril/valsartan)
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in NT-proBNP | Baseline (Month 0) to Month 12 | Change in NT-proBNP from baseline, measured by a quantitative point-of-care assay (e.g., Roche CARDIAC proBNP+) per the manufacturer's instructions. Also measured at Month 6. |
| Secondary | Change in LVEF | Baseline to Month 12 | Change in left ventricular ejection fraction measured by transthoracic echocardiography. |
| Secondary | Change in serum creatinine | Baseline to Month 12 | Change in serum creatinine from baseline. |
| Secondary | Change in eGFR | Baseline to Month 12 | Change in estimated glomerular filtration rate from baseline. |
| Secondary | Change in serum potassium | Baseline to Month 12 | Change in serum potassium from baseline. |
| Secondary | Change in KCCQ overall summary score | Baseline to Month 6 and Month 12 | Change in Kansas City Cardiomyopathy Questionnaire overall summary score (patient-reported health status). |
| Secondary | Cardiovascular death or first heart failure hospitalisation (composite) | Baseline to Month 12 | Proportion of participants experiencing cardiovascular death or first heart failure hospitalisation during the 12-month follow-up, ascertained at study visits and from medical records; time to first event estimated by Kaplan-Meier analysis. |
| Secondary | Adverse events and serious adverse events | From initiation of Savagen to Month 12 | Incidence, severity (mild, moderate, severe) and nature of all AEs and SAEs as defined by ICH-GCP and Malaysian GVP; relationship to study medication assessed by the site investigator. |
| Secondary | Adverse events of special interest | From initiation of Savagen to Month 12 | Incidence of hypotension, hyperkalaemia, renal impairment and angioedema. From initiation of Savagen to Month 12 |
| Secondary | Change in Dietary Diversity Score (DDS) | Baseline to Month 6 and Month 12 | Change in dietary diversity, measured as the number of predefined food groups consumed over the questionnaire recall period (FAO individual dietary diversity guidance); higher scores indicate greater diversity. Exploratory. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907640
GET https://conductscience.org/api/trials/v1/NCT07907640/registered